Investigating how a specific protein affects resistance to HER2 therapy in breast cancer
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer
This study is looking at how a protein called USP27X affects breast cancer cells' ability to resist treatments that target HER2, and it hopes to find ways to make these treatments work better for patients with HER2-positive breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11049174 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called USP27X in the resistance of breast cancer cells to HER2-targeting therapies. It aims to explore how overexpression of another protein, Cyclin D1, contributes to this resistance and how targeting USP27X could enhance the effectiveness of existing treatments. By studying the mechanisms behind these interactions, the research seeks to identify new therapeutic strategies that could improve patient outcomes. Patients may benefit from insights that could lead to more effective treatments for HER2-positive breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with HER2-positive breast cancer who have shown resistance to standard HER2-targeting therapies.
Not a fit: Patients with HER2-negative breast cancer or those who have not undergone HER2-targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with HER2 therapy-resistant breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Atanassov, Boyko S — Roswell Park Cancer Institute Corp
- Study coordinator: Atanassov, Boyko S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.